Akio Koyama
Overview
Explore the profile of Akio Koyama including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
114
Citations
944
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Usui J, Hirayama K, Kobayashi M, Suzuki S, Ebihara I, Nishiki K, et al.
Intern Med
. 2025 Feb;
PMID: 39993753
Objective We conducted a prospective, randomized controlled, open-label study to investigate the efficacy of a combination of cyclosporine and low-dose prednisolone in patients with idiopathic membranous nephropathy (IMN). Methods We...
2.
Yamada T, Tokuda T, Yoshioka N, Koyama A, Nishikawa R, Shimamura K, et al.
Ann Vasc Dis
. 2024 Dec;
17(4):396-404.
PMID: 39726548
Evidence for antithrombotic therapy after endovascular therapy (EVT) is limited. This retrospective, multicenter, observational study enrolled 732 consecutive patients with lower extremity artery disease who underwent EVT between January 2018...
3.
Yamada T, Tokuda T, Yoshioka N, Koyama A, Nishikawa R, Shimamura K, et al.
Catheter Cardiovasc Interv
. 2024 Dec;
105(3):698-706.
PMID: 39718411
Background: The impact of below-the-knee (BK) runoff after drug-coated balloon (DCB) treatment in femoropopliteal (FP) lesions has not been well investigated. Methods: This retrospective multicenter observational study enrolled 291 consecutive...
4.
5.
Yamada T, Tokuda T, Yoshioka N, Koyama A, Nishikawa R, Shimamura K, et al.
J Atheroscler Thromb
. 2023 Aug;
31(2):148-157.
PMID: 37558496
Aim: The accuracy of the DISFORM (diameter reduction, spiral shape, flow impairment, or adverse morphology) classification system has not been validated. Methods: This retrospective multicenter observational study enrolled 288 consecutive...
6.
Yamada T, Tokuda T, Yoshioka N, Koyama A, Nishikawa R, Shimamura K, et al.
Health Sci Rep
. 2023 Aug;
6(8):e1481.
PMID: 37547358
Background And Aims: Polymer-coated drug-eluting stents (Eluvia) have shown favorable clinical outcomes in real-world registries. There are no reports on recurrent predictors after Eluvia placement based on intravascular ultrasound (IVUS)...
7.
Tokuda T, Yoshioka N, Koyama A, Yamada T, Shimamura K, Nishikawa R
J Atheroscler Thromb
. 2023 Aug;
31(1):100-108.
PMID: 37532569
Aim: Lower-extremity artery disease (LEAD) is a high-risk factor for bleeding. However, the specific risk factors for bleeding in patients with LEAD remain unclear. We aimed to identify risk factors...
8.
Yoshioka N, Tokuda T, Koyama A, Yamada T, Shimamura K, Nishikawa R, et al.
J Endovasc Ther
. 2023 May;
32(2):439-451.
PMID: 37246791
Purpose: Endovascular therapies (EVTs) for symptomatic lower extremity peripheral artery disease (PAD) are efficient and minimally invasive. However, patients with PAD tend to have high bleeding risk (HBR), and there...
9.
Yoshioka N, Tokuda T, Koyama A, Yamada T, Shimamura K, Nishikawa R, et al.
J Atheroscler Thromb
. 2023 Mar;
30(11):1674-1686.
PMID: 36948637
Aim: Patients with chronic limb-threatening ischemia (CLTI) have a high bleeding risk (HBR) and mortality rate. The 2-year life expectancy is an important factor in deciding the appropriate treatment strategy....
10.
Yoshioka N, Tokuda T, Koyama A, Yamada T, Shimamura K, Nishikawa R, et al.
Heart Vessels
. 2022 Sep;
38(3):429-437.
PMID: 36169709
We aimed to assess the clinical performance and risk factors for patency loss within 2 years following the use of polymer-coated paclitaxel-eluting stents (PC-PESs) and drug-coated balloons (DCBs) in patients...